Amgen profit beats estimates, next MariTide studies start by mid-year
Amgen posted a higher quarterly profit on Tuesday, driven by an 11% rise in product sales, and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a hold on an early-stage trial of a different experimental weight-loss drug.
Pipeline Problems Mar Amgen’s Q4 Beat
Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 and the discontinuation of other programs.
Amgen Surpasses Q4 Earnings Forecasts
Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.
Amgen (AMGN) Q4 2024 Earnings Call Transcript
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js
Amgen Inc. Q4 Profit Decreases, But Beats Estimates
Amgen Inc. (AMGN) reported a profit for fourth quarter that decreased from the same period last year but beat the Street estimates.
Amgen: Q4 Earnings Snapshot
The average estimate of 13 analysts surveyed by Zacks Investment Research was for earnings of $5.03 per share. The world's largest biotech drugmaker posted revenue of $9.09 billion in the period, also beating Street forecasts.
Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics
Amgen (AMGN) reported $9.09 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 10.9%. EPS of $5.31 for the same period compares to $4.71 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $8.
Amgen Q4 Earnings Preview: Street expects revenue to rise more than 8%
Biopharmaceutical company Amgen (AMGN) is set to announce its fourth quarter earnings results on Tuesday, February 4th, after the closing bell. Wall Street expe
Amgen Discloses FDA Paused Study of Early-Stage Obesity Drug
Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs ...
Amgen Inc (AMGN) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions
Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...
Amgen profits rise, next MariTide studies start by mid-year
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...
AMGN Earnings: Amgen Slips on Soft EPS Guidance
Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...
STAT15h
Study of Amgen’s early obesity candidate paused by FDA
The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to ...
FierceBiotech16h
Amgen's early-stage obesity asset slapped with FDA hold
Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...
Amgen (AMGN) Receives a Hold from Truist Financial
Truist Financial analyst Srikripa Devarakonda maintained a Hold rating on Amgen (AMGN – Research Report) today and set a price target of ...
Open Source: Amgen CEO credited new NC factory to Trump tax cuts. Is he right?
The Tax Cuts and Jobs Act of 2017 reconfigured the tax code. Did it also enable a pharmaceutical giant to invest in Wake ...